RCD has advised the biopharmaceutical company, aptaTargets, on an agreement with the German multinational pharmaceutical company Merck KGaA for the clinical development and commercialisation of ApTOLL, a Toll-like receptor 4 (TLR4) antagonist being developed for acute ischaemic stroke
Latest news
We advised Fundeen, a participatory financing platform that specialises in renewable energy, on the investment of the IB Deuda España impact fund, managed by Impact Bridge, for up to EUR 11 M, including EUR 1 M for strengthening the development of its project portfolio and an additional EUR 10 M in co-financed projects in 2025
RCD advised Pet Snack, a company that specialises in manufacturing pet food under the leading brand, Mediterranean Natural, on the acquisition of a majority stake in its share capital by Alinatur, a company operating in the same sector
Cristian Valcárcel, Partner of our Bankruptcy Law Area, will participate as an expert in the I Insolvency Law Conference to be held on 12 and 13 June
Habitacion.com, a start-up that develops a platform for purchasing rooms in shared properties, has completed a funding round that will enable it to consolidate its leadership in the residential co-ownership market in Southern Europe


